Skip to main content
Erschienen in: Heart and Vessels 4/2013

01.07.2013 | Original Article

Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trial

verfasst von: Igor Mrdovic, Lidija Savic, Ratko Lasica, Gordana Krljanac, Milika Asanin, Natasa Brdar, Nemanja Djuricic, Natasa Cvetinovic, Jelena Marinkovic, Jovan Perunicic

Erschienen in: Heart and Vessels | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Stent thrombosis (ST) is an important cause of death after primary percutaneous coronary intervention (pPCI). This substudy aimed at evaluating the usefulness of the RISK-PCI score, originally developed for the prediction of 30-day major adverse cardiovascular events, to predict the occurrence of ST after pPCI. We analyzed 1972 consecutive patients who underwent pPCI with stent implantation between February 2007 and December 2009. Early ST (EST), late ST (LST), and cumulative 1-year ST (CST) were the predefined end points. Definite, probable, and possible ST were included. Models discrimination and calibration to predict ST was tested using receiver-operating characteristics curves and the goodness-of-fit (GoF) test. Sensitivity analyses and 1000-resample bootstrapping were used to evaluate the model’s performance. The rates of EST, LST, and CST were 4.6, 1.4, and 6.0 %, respectively. Compared with controls, the cumulative ST group was associated with much higher rates of adverse clinical outcomes at 30-day follow-up (adjusted odds ratio (OR) for death 6.45, adjusted OR for major bleeding 4.41) and at 12-month follow-up (adjusted OR for death 7.35, adjusted OR for major bleeding 4.56). Internal validation confirmed a reasonably good discrimination and calibration of the RISK-PCI score for the prediction of EST (area under the curve (AUC) 0.71, GoF 0.42), LST (AUC 0.69, GoF 0.36), and CST (AUC 0.70, GoF 0.22) after pPCI. ST after pPCI is associated with adverse 30-day and 1-year clinical outcomes. We conclude that the risk of ST could be accurately assessed using the RISK-PCI score, which might help in deciding upon measures aimed at preventing adverse prognosis.
Literatur
1.
Zurück zum Zitat Raber L, Windecker S (2011) Primary percutaneous coronary intervention and risk of stent thrombosis. A look beyond the HORIZON. Circulation 123:1709–1712PubMedCrossRef Raber L, Windecker S (2011) Primary percutaneous coronary intervention and risk of stent thrombosis. A look beyond the HORIZON. Circulation 123:1709–1712PubMedCrossRef
2.
Zurück zum Zitat Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ, for the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators (2002) Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346:957–966 Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ, for the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators (2002) Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346:957–966
3.
Zurück zum Zitat Horii M, Uemura S, Uemura M, Matsumoto M, Ishizashi H, Imagawa K, Iwama H, Takeda Y, Kawata H, Nakajima T, Fujimura Y, Saito Y (2008) Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation. Heart Vessels 23:301–307PubMedCrossRef Horii M, Uemura S, Uemura M, Matsumoto M, Ishizashi H, Imagawa K, Iwama H, Takeda Y, Kawata H, Nakajima T, Fujimura Y, Saito Y (2008) Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation. Heart Vessels 23:301–307PubMedCrossRef
4.
Zurück zum Zitat Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, Michalis LK, Serruys PW (2007) Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction. The importance of thrombus burden. J Am Coll Cardiol 50:573–583PubMedCrossRef Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, Michalis LK, Serruys PW (2007) Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction. The importance of thrombus burden. J Am Coll Cardiol 50:573–583PubMedCrossRef
5.
Zurück zum Zitat Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, Gold HK, Burke AP, Kolodgie FD, Virmani R (2008) Delayed arterial healing and increased late stent thrombosis at culprit sites after drug eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 118:1138–1145PubMedCrossRef Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, Gold HK, Burke AP, Kolodgie FD, Virmani R (2008) Delayed arterial healing and increased late stent thrombosis at culprit sites after drug eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 118:1138–1145PubMedCrossRef
6.
Zurück zum Zitat Lagerqvist B, Carlsson J, Frobert O, Lindback J, Schersten F, Stenestrand U, James SK (2007) Stent thrombosis in Sweden: a report from the Swedish Coronary Angiography and Angioplasty Registry. Circ Cardiovasc Interv 2:401–8 Lagerqvist B, Carlsson J, Frobert O, Lindback J, Schersten F, Stenestrand U, James SK (2007) Stent thrombosis in Sweden: a report from the Swedish Coronary Angiography and Angioplasty Registry. Circ Cardiovasc Interv 2:401–8
7.
Zurück zum Zitat Bavry AA, Bhatt DL (2007) Drug-eluting stents. Dual antiplatelet therapy for every survivor? Circulation 116:696–699PubMedCrossRef Bavry AA, Bhatt DL (2007) Drug-eluting stents. Dual antiplatelet therapy for every survivor? Circulation 116:696–699PubMedCrossRef
8.
Zurück zum Zitat Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M; the PLATO investigators (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057 Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M; the PLATO investigators (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057
9.
Zurück zum Zitat Aoki J, Lansky AJ, Mehran R, Moses J, Bertrand ME, McLaurin BT, Cox DA, Lincoff AM, Ohman EM, White HD, Parise H, Leon MB, Stone GW (2009) Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare-metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation 119:687–698PubMedCrossRef Aoki J, Lansky AJ, Mehran R, Moses J, Bertrand ME, McLaurin BT, Cox DA, Lincoff AM, Ohman EM, White HD, Parise H, Leon MB, Stone GW (2009) Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare-metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation 119:687–698PubMedCrossRef
10.
Zurück zum Zitat Airoldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L, Bonizzoni E, Carlino M, Gerckens U, Godino C, Melzi G, Michev I, Montorfano M, Sangiorgi GM, Qasim A, Chieffo A, Briguori C, Grube E (2007) Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116:745–754PubMedCrossRef Airoldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L, Bonizzoni E, Carlino M, Gerckens U, Godino C, Melzi G, Michev I, Montorfano M, Sangiorgi GM, Qasim A, Chieffo A, Briguori C, Grube E (2007) Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116:745–754PubMedCrossRef
11.
Zurück zum Zitat Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126–2130PubMedCrossRef Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126–2130PubMedCrossRef
12.
Zurück zum Zitat Schuhlen H, Kastrati A, Dirschinger J, Hausleiter J, Elezi S, Wehinger A, Pache J, Hadamitzky M, Schomig A (1998) Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 98:104–111PubMedCrossRef Schuhlen H, Kastrati A, Dirschinger J, Hausleiter J, Elezi S, Wehinger A, Pache J, Hadamitzky M, Schomig A (1998) Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 98:104–111PubMedCrossRef
13.
Zurück zum Zitat Fujii K, Carlier SG, Mintz GS, Yang YM, Moussa I, Weisz G, Dangas G, Mehran R, Lansky AJ, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB (2005) Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol 45:995–998PubMedCrossRef Fujii K, Carlier SG, Mintz GS, Yang YM, Moussa I, Weisz G, Dangas G, Mehran R, Lansky AJ, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB (2005) Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol 45:995–998PubMedCrossRef
14.
Zurück zum Zitat Mrdovic I, Savic L, Perunicic J, Asanin M, Lasica R, Marinkovic J, Vasiljevic Z, Ostojic (2009) Development and validation of a risk scoring model to predict net adverse cardiovascular outcomes after primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel. Rationale and design of the RISK-PCI study. J Interv Cardiol 22:320–328 Mrdovic I, Savic L, Perunicic J, Asanin M, Lasica R, Marinkovic J, Vasiljevic Z, Ostojic (2009) Development and validation of a risk scoring model to predict net adverse cardiovascular outcomes after primary percutaneous coronary intervention in patients pretreated with 600 mg clopidogrel. Rationale and design of the RISK-PCI study. J Interv Cardiol 22:320–328
15.
Zurück zum Zitat Mrdovic I, Savic L, Krljanac G, Perunicic J, Asanin M, Lasica R, Marinkovic J, Vasiljevic Z, Ostojic M (2011) Predicting 30-day Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention. The RISK-PCI score. Int J Cardiol. doi:10.1016/J.ijcard.2011.05.071 Mrdovic I, Savic L, Krljanac G, Perunicic J, Asanin M, Lasica R, Marinkovic J, Vasiljevic Z, Ostojic M (2011) Predicting 30-day Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention. The RISK-PCI score. Int J Cardiol. doi:10.​1016/​J.​ijcard.​2011.​05.​071
16.
Zurück zum Zitat Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351 Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351
17.
Zurück zum Zitat Honda Y, Fitzgerald PJ (2003) Stent thrombosis: an issue revisited in a changing world. Circulation 108:2–5PubMedCrossRef Honda Y, Fitzgerald PJ (2003) Stent thrombosis: an issue revisited in a changing world. Circulation 108:2–5PubMedCrossRef
18.
Zurück zum Zitat Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice. Lancet 369:667–678PubMedCrossRef Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice. Lancet 369:667–678PubMedCrossRef
19.
Zurück zum Zitat Wenaweser P, Rey C, Eberli FR, Togni M, Tuller D, Locher S, Remondino A, Seiler C, Hess OM, Meier B, Windecker S (2005) Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J 26:1180–1187PubMedCrossRef Wenaweser P, Rey C, Eberli FR, Togni M, Tuller D, Locher S, Remondino A, Seiler C, Hess OM, Meier B, Windecker S (2005) Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J 26:1180–1187PubMedCrossRef
20.
Zurück zum Zitat Tolleson TR, Newby LK, Harrington RA, Bhapkar MV, Verheugt FWA, Berger PB, Moliterno DJ, White HD, Ohman EM, van de Werf F, Topol EJ, Califf RM, for the SYMPHONY and the 2nd SYMPHONY Investigators (2003) Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). Am J Cardiol 92:330–333 Tolleson TR, Newby LK, Harrington RA, Bhapkar MV, Verheugt FWA, Berger PB, Moliterno DJ, White HD, Ohman EM, van de Werf F, Topol EJ, Califf RM, for the SYMPHONY and the 2nd SYMPHONY Investigators (2003) Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). Am J Cardiol 92:330–333
21.
Zurück zum Zitat Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, for the TRITON–TIMI 38 Investigators (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015 Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, for the TRITON–TIMI 38 Investigators (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015
22.
Zurück zum Zitat Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, Slama MS, Merkely B, Erglis A, Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode C (2006) Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355:1093–1104PubMedCrossRef Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, Slama MS, Merkely B, Erglis A, Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode C (2006) Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355:1093–1104PubMedCrossRef
23.
Zurück zum Zitat Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AL, Cristea E, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Moeckel M, Stone GW, for the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial Investigators (2011) Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation 123:1745–1756 Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AL, Cristea E, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Moeckel M, Stone GW, for the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial Investigators (2011) Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation 123:1745–1756
24.
Zurück zum Zitat Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Seyfarth M, Varenne O, Dirksen MT, Percoco G, Varricchio A, Pittl U, Syvanne M, Suttorp MJ, Violini R, Schomig A (2007) Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 28:2706–2713PubMedCrossRef Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Seyfarth M, Varenne O, Dirksen MT, Percoco G, Varricchio A, Pittl U, Syvanne M, Suttorp MJ, Violini R, Schomig A (2007) Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 28:2706–2713PubMedCrossRef
25.
Zurück zum Zitat Mehta RH, Ou FS, Peterson ED, Shaw RE, Hillegass Jr WB, Rumsfeld JS, Roe MT, for the American College of Cardiology–National Cardiovascular Database Registry Investigators (2009) Cinical significance of post-procedural TIMI flow in patients with cardiogenic shock undergoing primary percutaneous coronary intervention. JACC Cardiovasc Interv 2:56–64 Mehta RH, Ou FS, Peterson ED, Shaw RE, Hillegass Jr WB, Rumsfeld JS, Roe MT, for the American College of Cardiology–National Cardiovascular Database Registry Investigators (2009) Cinical significance of post-procedural TIMI flow in patients with cardiogenic shock undergoing primary percutaneous coronary intervention. JACC Cardiovasc Interv 2:56–64
26.
Zurück zum Zitat Mariani M, Fetiveau R, Rosseti E, Poli A, Poletti F, Vandoni P, D’Urbano M, Cafiero F, Mariani G, Klersy C, De Servi S (2006) Significance of total and differential leukocyte count in patients with acute myocardial infarction treated with primary coronary angioplasty. Eur Heart J 27:2511–2515PubMedCrossRef Mariani M, Fetiveau R, Rosseti E, Poli A, Poletti F, Vandoni P, D’Urbano M, Cafiero F, Mariani G, Klersy C, De Servi S (2006) Significance of total and differential leukocyte count in patients with acute myocardial infarction treated with primary coronary angioplasty. Eur Heart J 27:2511–2515PubMedCrossRef
27.
Zurück zum Zitat Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC, Kim SW, Bui A, Gevorkian N, Xue Z, Smith K, Fournadjieva J, Suddath WO, Satler LF, Pichard AD, Kent KM, Waksman R (2006) Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113:1108–1113PubMedCrossRef Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC, Kim SW, Bui A, Gevorkian N, Xue Z, Smith K, Fournadjieva J, Suddath WO, Satler LF, Pichard AD, Kent KM, Waksman R (2006) Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113:1108–1113PubMedCrossRef
28.
Zurück zum Zitat Ferrari E, Benhamou M, Cerboni P, Marcel B (2005) Coronary syndromes following aspirin withdrawal. J Am Coll Cardiol 45:456–459PubMedCrossRef Ferrari E, Benhamou M, Cerboni P, Marcel B (2005) Coronary syndromes following aspirin withdrawal. J Am Coll Cardiol 45:456–459PubMedCrossRef
29.
Zurück zum Zitat Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, Hong MK, Kim JJ, Park SJ (2006) Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 98:352–356PubMedCrossRef Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, Hong MK, Kim JJ, Park SJ (2006) Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 98:352–356PubMedCrossRef
30.
Zurück zum Zitat Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, Messenger JC, Khanal S, Peterson ED, Bach RG, Krumholz HM, Cohen DJ (2006) Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement. Circulation 113:2803–2809PubMedCrossRef Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, Messenger JC, Khanal S, Peterson ED, Bach RG, Krumholz HM, Cohen DJ (2006) Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement. Circulation 113:2803–2809PubMedCrossRef
31.
Zurück zum Zitat Mauri L, Hsieh W, Massaro JM, Ho KKL, D’Agostino R, Cutlip DE (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356:1020–1029PubMedCrossRef Mauri L, Hsieh W, Massaro JM, Ho KKL, D’Agostino R, Cutlip DE (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356:1020–1029PubMedCrossRef
32.
Zurück zum Zitat Wenaweser P, Dörffler-Melly J, Imboden K, Windecker S, Togni M, Meier B, Haeberli A, Hess OM (2005) Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 45:1748–1752PubMedCrossRef Wenaweser P, Dörffler-Melly J, Imboden K, Windecker S, Togni M, Meier B, Haeberli A, Hess OM (2005) Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 45:1748–1752PubMedCrossRef
33.
Zurück zum Zitat Moussa I, Di Mario C, Reimers B, Akiyama T, Tobis J, Colombo A (1997) Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol 29:6–12PubMedCrossRef Moussa I, Di Mario C, Reimers B, Akiyama T, Tobis J, Colombo A (1997) Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol 29:6–12PubMedCrossRef
34.
Zurück zum Zitat Muraoka Y, Sonoda S, Tsuda Y, Tanaka S, Okazaki M, Otsuji Y (2011) Effect of intravascular ultrasound-guided adjuvant high-pressure non-compliant balloon post-dilation after drug-eluting stent implantation. Heart Vessels 26:565–571PubMedCrossRef Muraoka Y, Sonoda S, Tsuda Y, Tanaka S, Okazaki M, Otsuji Y (2011) Effect of intravascular ultrasound-guided adjuvant high-pressure non-compliant balloon post-dilation after drug-eluting stent implantation. Heart Vessels 26:565–571PubMedCrossRef
35.
Zurück zum Zitat Tanaka N, Pijls NHJ, Koolen JJ, Botman KJ, Michels HR, Brueren BRG, Peels K, Shindo N, Yamashita Y, Yamashina A (2011) Assessment of optimum stent deployment by stent boost imaging: comparison with intravascular ultrasound. Heart Vessels. doi:10.1007/s00380-011-0202-9 Tanaka N, Pijls NHJ, Koolen JJ, Botman KJ, Michels HR, Brueren BRG, Peels K, Shindo N, Yamashita Y, Yamashina A (2011) Assessment of optimum stent deployment by stent boost imaging: comparison with intravascular ultrasound. Heart Vessels. doi:10.​1007/​s00380-011-0202-9
36.
Zurück zum Zitat Boden H, van der Hoeven BL, Liem SS, Atary JZ, Cannegieter SC, Atsma DE, Bootsma M, Jukema JW, Zeppenfeld K, Oemrawsingh PV, van der Wall EE, Schalij MJ (2012) Five-year clinical follow-up from the MISSION intervention study: sirolimus-eluting stent versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial. EuroIntervention 7:1021–1029PubMedCrossRef Boden H, van der Hoeven BL, Liem SS, Atary JZ, Cannegieter SC, Atsma DE, Bootsma M, Jukema JW, Zeppenfeld K, Oemrawsingh PV, van der Wall EE, Schalij MJ (2012) Five-year clinical follow-up from the MISSION intervention study: sirolimus-eluting stent versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial. EuroIntervention 7:1021–1029PubMedCrossRef
Metadaten
Titel
Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trial
verfasst von
Igor Mrdovic
Lidija Savic
Ratko Lasica
Gordana Krljanac
Milika Asanin
Natasa Brdar
Nemanja Djuricic
Natasa Cvetinovic
Jelena Marinkovic
Jovan Perunicic
Publikationsdatum
01.07.2013
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 4/2013
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-012-0276-z

Weitere Artikel der Ausgabe 4/2013

Heart and Vessels 4/2013 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.